Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding AG    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Roche : says 59% of SMA patients getting Evrysdi can sit - trial data

share with twitter share with LinkedIn share with facebook
09/28/2020 | 01:18am EDT

ZURICH, Sept 28 (Reuters) - Swiss drugmaker Roche on Monday said 59% of infants with the severest form of spinal muscular atrophy could sit for at least five seconds after getting its drug Evrysdi for two years, according to trial data, up from 33% after a year of treatment.

"We are highly encouraged by the results we are seeing in the second year of treatment with Evrysdi," Roche said, adding that 18 of the 21 patients in the Firefish trial of patients with Type 1 SMA were still alive without needing permanent ventilation. Evrysdi was approved in August. (Reporting by John Miller; editing by Thomas Seythal)


share with twitter share with LinkedIn share with facebook
All news about ROCHE HOLDING AG
03:54pROCHE : COVID SCIENCE-COVID-19 complication rates far higher than for flu; open ..
RE
01:36pPROTHENA : Shares Rise 7% on Prasinezumab Study With Roche
DJ
09:22aPTC Therapeutics Says Evrysdi Approved in Brazil, Japan NDA Filed
DJ
07:57aROCHE : and Prothena will Advance Prasinezumab into Late-Stage Clinical Developm..
AQ
10/20ROCHE : announces full FDA approval for Venclexta combinations for acute myeloid..
AQ
10/20Chugai and Welby Launch a Treatment Support Personal Health Record Service fo..
AQ
10/19ROCHE : Genentech Announces Full FDA Approval for Venclexta Combinations for Acu..
AQ
10/19ROCHE HOLDINGS AG : JP Morgan reaffirms its Buy rating
MD
10/19ROCHE : announces full FDA approval for Venclexta combinations for acute myeloid..
AQ
10/19ROCHE : announces full FDA approval for Venclexta combinations for acute myeloid..
PU
More news
Financials
Sales 2020 60 427 M 66 754 M 66 754 M
Net income 2020 14 685 M 16 223 M 16 223 M
Net cash 2020 3 204 M 3 539 M 3 539 M
P/E ratio 2020 17,7x
Yield 2020 3,10%
Capitalization 256 B 283 B 283 B
EV / Sales 2020 4,18x
EV / Sales 2021 3,85x
Nbr of Employees 97 735
Free-Float 83,6%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 379,15 CHF
Last Close Price 299,15 CHF
Spread / Highest target 47,8%
Spread / Average Target 26,7%
Spread / Lowest Target 3,63%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
Paul Bulcke Non-Executive Director
André S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING AG-2.21%289 156
JOHNSON & JOHNSON-0.90%380 575
PFIZER INC.-3.52%208 327
MERCK & CO., INC.-13.94%197 964
NOVARTIS AG-15.38%188 853
NOVO NORDISK A/S16.64%166 534